Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Twist Bioscience Corp — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.62 (market cap $157.51B), while Twist Bioscience Corp trades at $122.96 (market cap $7.82B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 20.1× Twist Bioscience Corp's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| BBVA | TWST | |
|---|---|---|
Market Cap | $157.51B | $7.82B |
Sector | Financials | Health |
52-Week High | $28.36 | $124.88 |
52-Week Low | $17.96 | $24.16 |
Dividend Yield | 3.8% | — |
Enterprise Value | — | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.35, up 0.75% today, with a bullish technical signal from moving averages and strong fundamental performance. The bank reported Q2 2026 net profit growth of 11.4% year-over-year, driven by Mexico operations, and announced a $2.3 billion buyback. Revenue reached $39.42 billion in 2025, with net income margin at 26.13% and ROE of 18.5%, though cash flow was negative in 2024.
Outlook is positive with raised profitability guidance (ROTE ~21%) and analyst consensus leaning buy (54%), but risks include a Spanish court trial for spying allegations and antitrust probes. The stock offers value with a P/E of 12.98, yet investors should monitor legal overhangs and macroeconomic volatility in core markets like Spain and Mexico.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
